Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

BIOCRYST Form 4 June 01, 20	ГРНАRMACEU 09	FICALS II	NC									
FORM										OMB	APPROVAL	
	UNITED	STATES				AND EX , D.C. 2			COMMISSION	OMB Number:	3235-0287	
Check t				0		,				Expires:	January 31,	
if no longer subject to Section 16. Form 4 or Form 5 Filed pursuant to Section				SEC	CUI	RITIES				Estimated burden ho response	ours per	
obligati may con <i>See</i> Inst 1(b).	ons ntinue. Section 17((a) of the l	Public U	Jtility I	Hol	lding Co	mpa	•	1935 or Sectio	n		
(Print or Type	Responses)											
	Address of Reporting tal (GP), LLC	Person <u>*</u>	Symbol	RYST I	PH	d Ticker o		^{ding} ΓICALS	5. Relationship of Issuer (Cheo	f Reporting Po ck all applicat		
(Last) (First) (Middle) 3. Date of				of Earliest Transaction n/Day/Year)					Director _X_ 10% Owner Officer (give title Other (specify below)			
NEW YOF	(Street) RK, NY US 10021	l	4. If Am Filed(Mo			Date Origin ar)	nal		6. Individual or J Applicable Line) Form filed by (_X_ Form filed by Person	One Reporting	Person	
(City)	(State)	(Zip)	Tat	ole I - N	on-	Derivativ	e Seci	urities Acq	uired, Disposed o	f, or Benefici	ally Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		ed Date, if	d 3. 4. Securities Acquired Date, if Transactior(A) or Disposed of (D) Code (Instr. 3, 4 and 5) y/Year) (Instr. 8) (A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
$\frac{\text{Common}}{\text{Stock } (1)}$	05/28/2009			S	·	Amount 2,597	(D) D	Price \$ 4.4535	134,091	I	Through Partnership (3) (4)	
$\begin{array}{c} \text{Common} \\ \text{Stock} \ \underline{(1)} \\ \underline{(2)} \end{array}$	05/28/2009			S		4,677	D	\$ 4.5041	129,414	Ι	Through Partnership (3) (4)	
$\begin{array}{c} \text{Common} \\ \text{Stock} \ \underline{(1)} \\ \underline{(2)} \end{array}$	05/29/2009			S		631	D	\$ 4.3013	128,783	I	Through Partnership (3) (4)	
Common	05/29/2009			S		3,249	D	\$	125,534	I	Through	

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

Stock (1) (2)					4.1228			Partnership (3) (4)
$\begin{array}{c} \text{Common} \\ \text{Stock} \ \underline{(1)} \\ \underline{(2)} \end{array}$	06/01/2009	S	3,392	D	\$ 3.8641	122,142	Ι	Through Partnership (3) (4)
$\frac{\text{Common}}{\text{Stock } (1)}$	06/01/2009	S	1,314	D	\$ 3.885	120,828	Ι	Through Partnership (3) (4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)		4. Transactio	5. onNumber	6. Date Exer Expiration D		7. Title Amour		8. Price of Derivative	9. Nu Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Underl		Security	Secu
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securit	ties	(Instr. 5)	Bene
	Derivative				Securities			(Instr.	3 and 4)		Owne
	Security				Acquired						Follo
					(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									Amount		
						Date Exercisable	Expiration Date	Title	or Number		

Code V (A) (D)

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
14159 capital (GP), LLC 667 MADISON AVENUE, 17TH FLOOR NEW YORK, NY US 10021		Х				
BAKER JULIAN 667 MADISON AVENUE, 17TH FLOOR NEW YORK, NY US 10021		Х				
BAKER FELIX 667 MADISON AVENUE, 17TH FLOOR NEW YORK, NY US 10021		Х				

Shares

Date

Date

06/01/2009

Date

Signatures

/s/ Julian C. Baker, as Managing Member of 14159 Capital (GP) 06/01/2009 LLC **Signature of Reporting Person /s/ Julian C. Baker 06/01/2009 **Signature of Reporting Person

/s/ Felix J. Baker

**Signature of Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

In addition to 14159 Capital (GP), LLC, this Form 4 is being filed jointly by Julian C. Baker and Felix J. Baker, each of whom has the same business address as 14159 Capital (GP), LLC and may be deemed to have a pecuniary interest in securities owned by it. Because of

(1) certain relationships with other security holders of the Issuer, the Reporting Persons are filing solely for informational purposes as if they were a member of a group of such shareholders. (Continued in footnote 2).

However, the Reporting Persons disclaim that they and any other person or persons, in fact constitute a "group" for purposes of Section

13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder or that they are the beneficial owners of securities (2) owned by any such other persons, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein.

Represents securities owned directly by 14159, L.P., the sole general partner of which is 14159 Capital, L.P., a limited partnership the (3) sole general partner of which is 14159 Capital (GP),LLC. Julian C. Baker and Felix J. Baker are the controlling members of 14159 Capital (GP), LLC.

Stephen R. Biggar, an employee of Baker Bros. Advisors LLC, is a Director of the Company. Baker Bros. Advisors, LLC is the (4) Management Company of 14159, L.P.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.